<unk>  (INN; EU trade name Brinavess; proposed US trade name Kynapid) is a pharmaceutical drug for the acute conversion of atrial fibrillation, a kind of irregular heartbeat, in form of an intravenous infusion. It has been approved for use in the European Union and the UK since 2010. The US Food and Drug Administration denied approval in 2008 and 2019.
Vernakalant
Bocasan
Atogepant
Tasimelteon
Seltorexant
Pulmocide
Veristrat
Bretylium